NASDAQ:EPOC - Epocrates Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$11.73 0.00 (0.00 %)
(As of 06/24/2018 04:00 PM ET)
Previous Close$11.73
Today's RangeN/A
52-Week Range$6.90 - $11.97
VolumeN/A
Average Volume228,735 shs
Market Capitalization$291.75 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Epocrates logoEpocrates, Inc. (Epocrates) is a provider of mobile drug reference tools and electronic health records to healthcare professionals and interactive services to the healthcare industry. As of December 31, 2011, its user network consists of well over one million healthcare professionals, including approximately 340,000, or more than 50% of United States physicians. The Company offers its products on major United States mobile platforms, including Apple iOS, Android and BlackBerry. Epocrates operates in two segments: Subscriptions and Interactive Services, and Electronic Health Records. It uses brand names include DocAlert, Epocrates, Epocrates Honors, Epocrates ID, Epocrates Lab, Epocrates MedTools, Epocrates Rx, Epocrates Rx Pro, Epocrates Dx, Epocrates QuickSurvey, Epocrates QuickRecruit, Epocrates MedInsight, EssentialPoints and MedCafe. In October 2011, it launched a redesign of the drug reference tool to create a new platform that provides healthcare professionals.

Receive EPOC News and Ratings via Email

Sign-up to receive the latest news and ratings for EPOC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:EPOC
CUSIPN/A
Phone+1-415-4163500

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A

The Truth About Cryptocurrencies

Epocrates (NASDAQ:EPOC) Frequently Asked Questions

What is Epocrates' stock symbol?

Epocrates trades on the NASDAQ under the ticker symbol "EPOC."

Has Epocrates been receiving favorable news coverage?

News coverage about EPOC stock has trended somewhat positive on Sunday, Accern reports. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Epocrates earned a news sentiment score of 0.17 on Accern's scale. They also gave news headlines about the company an impact score of 46.34 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

How do I buy shares of Epocrates?

Shares of EPOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Epocrates' stock price today?

One share of EPOC stock can currently be purchased for approximately $11.73.

How big of a company is Epocrates?

Epocrates has a market capitalization of $291.75 million.

How can I contact Epocrates?

Epocrates' mailing address is 50 Hawthorne, SAN FRANCISCO, CA 94105, United States. The company can be reached via phone at +1-415-4163500.


MarketBeat Community Rating for Epocrates (EPOC)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  64 (Vote Outperform)
Underperform Votes:  70 (Vote Underperform)
Total Votes:  134
MarketBeat's community ratings are surveys of what our community members think about Epocrates and other stocks. Vote "Outperform" if you believe EPOC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPOC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.